Bengt von Mentzer

Dr. Ph.D.

Roles in PharmNovo: Founder, President, Chief scientific advisor and Director of the board.

Born: 1949.

Education: PhD in Zoophysiology, Medical Physiology/Pharmacology, Histology.

Other current appointments: None.

Work experience: AstraZeneca 30 years. Visiting Fellow at University of Leicester 1.5 years, University of Iowa and University of Boston 1.5 year. Employed at AZ at the departments of Physiology, Bioscience, Pharmacology and Molecular Pharmacology. Principal scientist, group leader in IBS pain Molecular Pharmacology.

Holdings: 652 000 shares.

Member of:

Board of directors

Operational team

Latest news

View all

March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Meet Bengt von Mentzer, founder and Chief scientific advisor

March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Meet Olof Breuer, MD, Clinical pharmacology lead

January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.